Oculis Q2 2026 loss narrows on CHF 12.1 million warrant valuation gain, FX swing to profit

Research and development expense edged down 1% to CHF 29.33 million as wind-down of the OCS-01 DIAMOND trial cut external costs, partly offset by the ramp of PIONEER-1.

General and administrative expense rose 42% to CHF 16.49 million, driven mainly by higher share-based compensation from new equity grants and higher grant values.

Cash, cash equivalents and short-term financial assets totaled CHF 228.3 million at June 30, 2026. Operating cash outflow was CHF 35.57 million.

Oculis said it raised CHF 47.8 million gross from selling 2,250,000 shares through its at-the-market program. The company also said no FDA filing is planned for OCS-01 in diabetic macular edema after Phase 3 endpoints were missed.

Oculis said its six months ended June 30, 2026 loss narrowed to CHF 38.82 million from CHF 58.59 million, helped by a swing in finance result.